Myomo gets US nod for "smart" paralysis brace:
This article was originally published in Clinica
Executive Summary
The US FDA has approved a noninvasive, wearable, "smart" elbow brace that can help patients whose arms have become paralysed following a stroke relearn how to move their upper limbs. The Myomo e100 NeuroRobotic system, made by Boston, Massachusetts-based firm Myomo, enables patients to self-initiate and control movement of affected limbs using their own biological signals. No electrical stimulation or surgery is required. When a patient's electrical muscle activity signal fires in response to attempted movement, the device senses the signal from the skin's surface. It then employs advanced robotics to "reward" the patient with feedback in the form of actual motion. The theory is that by facilitating the patient's ability to practise tasks repeatedly, new connections are formed in the brain and existing connections are reinforced, resulting in improved ability to move the arm.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.